Imfinzi Adds Approval In Early-Stage Lung Cancer, Matching Keytruda

 
• By Joseph Haas

AstraZeneca is working to bolster its PD-L1 agent’s applicability in resectable non-small cell lung cancer, seeking advantages versus Merck’s Keytruda and Bristol’s Opdivo.

AZN
AstraZeneca adds early-stage lung cancer perioperative indication to Imfinzi's label • Source: Shutterstock

More from New Products

More from Scrip